Novo Nordisk Delivers Strong Financial Results Amid Rising Competition
Novo Nordisk just posted another set of strong numbers. The Danish drugmaker behind Ozempic and Wegovy reported a sharp rise in profit and sales, even as new rivals enter the weight-loss drug market. We’re talking about a 32% jump in quarterly net profit to DKK 26.5 billion ($3.85 billion) and continued demand for its blockbuster obesity and diabetes medicines.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
